news
Yescarta® demonstrates promising European manufacturing experience
In newly published analysis, Kite's CAR T-cell therapy delivered a reduced median European manufacturing turnaround time for diffuse large B-cell lymphoma (DLBCL) patients.
List view / Grid view
Kite
news
Kite releases pivotal CAR T therapy Phase III study results
Yescarta® is the first treatment in over 30 years to show statistically significant improvement in overall survival in R/R large B-cell lymphoma versus historical SOC.
news
First CAR T-cell therapy recommended on NHS
NICE’s recommendation of Yescarta® means it is the first time patients will be able to access CAR T-cell therapy long-term on the NHS.
news
EC approves CAR T-Cell therapy for B-cell lymphoma
Yescarta approved by EC for the treatment of large B-Cell lypmphoma and high grade B-cell lymphoma.
news
BioNTech strengthens neoantigen TCR programme with Kite acquisition
BioNTech acquires Kite’s solid tumour neoantigen T cell receptor research platform and Gaithersburg manufacturing facility for undisclosed amount.
news
CAR T therapy achieves high remission rate in acute lymphoblastic leukaemia trial
Trial data shows 71 percent of adult B cell acute lymphoblastic leukaemia patients receiving Tecartus® autologous anti-CD19-transduced CD3+ cell infusion achieved complete remission.
news
NICE recommends new CAR T-cell therapy to treat mantle cell lymphoma
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
news
EC approves KTE-X19 for treatment of mantle cell lymphoma
KTE-X19, an investigational CAR T-cell therapy, has been granted marketing authorisation by the European Commission.
